ERBB2 and breast carcinoma: We analyzed the difference in survival rates according to the expression of PDGFRA in HER2+ breast cancer patients and further investigated the efficacy of PDGFR inhibitors such as ponatinib or sunitinib for the treatment of TRZ-resistant breast cancer.